<DOC>
	<DOC>NCT02371161</DOC>
	<brief_summary>A phase II prospective, non-randomized study. The study aim is to evaluate the feasibility and activity of high-dose therapy with stem cell in elderly patients with aggressive lymphoma relapsed FIT or resistant to first line therapy.</brief_summary>
	<brief_title>Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy</brief_title>
	<detailed_description>The study aim is to evaluate the toxicity and activity of a therapeutic approach to high doses with support of peripheral blood stem cells (PBSC) in patients aged ≥ 65 and ≤75 years, chemosensitive relapsed or refractory to therapy first line in terms of event free survival (EFS) and treatment related mortality (TRM)</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Diagnosis of NHL relapse and refractory pts age ≥ 65 and ≤75 ECOG performance status &lt;2 FIT patients (Instrumental Activity of Daily Living (IADL)=8, Activity of Daily Living (ADL)=6, Cumulative Illness Rating Scale (CIRS) =0 SCORE=34, &lt;5 SCORE=2 ) evaluable disease no RT since 3 week absolute neutrophil count &gt;= 1500/mm3 and platelets &gt;= 100.000/106L Creatinin &lt;= 1.5 mg/dL and clearance &gt;40 ml/min/24 h bilirubins &lt; =2 mg/dL forced expiratory volume &gt;50% arterial pressure O2 &gt;70 mmHg no other neoplastic disease Life expectancy&gt; 3 months signed informed consent HBV+ HCV+ HIV+ NSC involvement medullar infiltration &gt; 20% other chemotherapy or radiotherapy cardiac disease alteration of liver and kidney function infections demented patient no compliance and depressed pts Frail and Unfit pts</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>